Candriam SCA’s Cymabay Therapeutics CBAY Stock Holding History

Candriam SCA’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-338,000	Closed	-$1.73M	–	809
2019 Q3	$1.73M	Sell	338,000 -40,000	-11%	-$242K	0.02%	522
2019 Q2	$2.69M	Sell	378,000 -600,000	-61%	-$6.79M	0.03%	449
2019 Q1	$13M	Hold	978,000	–	–	0.17%	142
2018 Q4	$7.7M	Buy	978,000 +20,000	+2%	+$190K	0.12%	200
2018 Q3	$10.6M	Buy	958,000 +488,000	+104%	+$6.06M	0.14%	180
2018 Q2	$6.31M	Buy	470,000 +225,000	+92%	+$2.82M	0.1%	255
2018 Q1	$3.18M	Buy	245,000 +110,000	+81%	+$1.37M	0.05%	374
2017 Q4	$1.24M	Buy	+135,000	New	+$1.15M	0.02%	552

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Candriam SCA's CBAY Position: Q4 2019 in Review

Candriam SCA sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 338,000 shares — an estimated $1.73M sold.

Candriam SCA first reported a position in CBAY in Q4 2017 and held it in 8 quarters. The position peaked at $13M in Q1 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

Candriam SCA reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
Candriam SCA sold 338,000 Cymabay Therapeutics shares in Q4 2019, an estimated $1.73M.
Candriam SCA first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 8 quarters.
Candriam SCA's Cymabay Therapeutics position peaked at $13M in Q1 2019.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.